As another side note, looks like Novartis is gearing up for a $7 billion buyout of The Medicine's Company for the inclisiran PCSK9 RNAi drug. $85 per share for MDCO is the rumor (not finalized yet). Article says deal is worth close to $10 billion using a fully diluted share count. And this is without a completed CVOT or approved drug. The MDCO Orion LDL-C Phase 3 lowering program just wrapped up and NDA/MAA applications to FDA/EMA havne't even been submitted yet.

Should that be the case, then I reckon we should be good for a measily $4B.